Patient Assistance Programs Main Article
Patient Assistance Program

Compassion for patients.
A commitment to ensuring that our medicines are available to those who need them most is just as important as our commitment to developing innovative treatments. We are committed to helping patients get the medications they need by providing a wide array of support services to help with access to our treatments.
Daiichi Sankyo Access Central provides support and information to help patients access our products, including providing product at no cost to eligible uninsured or underinsured patients.
For more information, visit the Daiichi Sankyo Access Central website to learn more about medication coverage and access support, financial assistance and other helpful resources.
Daiichi Sankyo products covered:
ENHERTU®
([fam-] trastuzumab deruxtecan nxki)
See full prescribing information including boxed warnings and medication guide
INJECTAFER®
(ferric carboxymaltose injection)
See full prescribing information
TURALIO®
(pexidartinib)
See full prescribing information including boxed warning regarding liver toxicity and medication guide

Partnership for Prescription Assistance
Daiichi Sankyo, Inc. is also a proud member of Pharmaceutical Research and Manufacturers of America's Partnership for Prescription Assistance (PPA) program. The PPA is a national coalition of pharmaceutical companies, doctors and other healthcare providers, pharmacists, patient advocates and community groups. PPA helps patients identify potential assistance programs, assess potential eligibility, and obtain enrollment forms. Visit www.pparx.org
Patient Assistance Programs More Stories
More Stories

Reporting Adverse Reactions
Please report any adverse reactions to our products to the Daiichi Sankyo Contact Center at 1-877-4 DS-PROD (1-877-437-7763).
read more ...